Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been assigned an average rating of “Moderate Buy” from the seventeen analysts that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $55.38.

Several research firms have issued reports on KYMR. Stephens began coverage on Kymera Therapeutics in a research note on Monday, November 18th. They set an “overweight” rating and a $65.00 target price for the company. BTIG Research began coverage on Kymera Therapeutics in a research note on Tuesday, December 10th. They set a “buy” rating and a $60.00 target price for the company. Oppenheimer raised their target price on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Friday, September 27th. Truist Financial reissued a “buy” rating and set a $53.00 target price (down previously from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Finally, Leerink Partners reissued an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $41.59 on Friday. Kymera Therapeutics has a one year low of $22.35 and a one year high of $53.27. The stock has a market cap of $2.69 billion, a PE ratio of -17.77 and a beta of 2.16. The stock has a 50 day moving average price of $44.67 and a 200 day moving average price of $43.73.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. The company had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm’s quarterly revenue was down 20.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.90) EPS. As a group, analysts predict that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KYMR. Values First Advisors Inc. purchased a new position in Kymera Therapeutics in the third quarter valued at $61,000. Quarry LP purchased a new stake in Kymera Therapeutics during the 3rd quarter worth about $95,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Kymera Therapeutics by 27.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after buying an additional 504 shares during the last quarter. Public Employees Retirement Association of Colorado purchased a new stake in Kymera Therapeutics during the 2nd quarter worth about $139,000. Finally, Quest Partners LLC lifted its holdings in Kymera Therapeutics by 1,402.0% during the 2nd quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock worth $156,000 after buying an additional 4,865 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.